Results for: real-world evidence

In Press: Vedolizumab may have a real-life corticosteroid sparing effect

Vedolizumab may have a corticosteroid sparing effect in real-world clinical practice, a new Finnish study reveals. The incidence of inflammatory bowel disease (IBD), which include ulcerative colitis (UC) and Crohn’s disease (CD), is increasing worldwide. Accumulating data from clinical trials and real-world studies has demonstrated that vedolizumab, an anti-integrin antibody, is an effective and well-tolerated… Read more »

Finland has major competitive advantages for RWE research shows recent study conducted by MedEngine

Finland is in a good position to begin building a globally competitive ecosystem for real-world data (RWD) research, a qualitative survey conducted by MedEngine reveals. The survey was requested by the Pharma Industry Research Foundation and the results were presented at the Pharma Industry Finland Autumn meeting on November 21st, 2018. Real-world data and real-world… Read more »

MedEngine presented novel IBD and lung cancer data at the ISPOR congress in Barcelona

The 21st Annual European Congress of The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is currently (Nov 10–14th 2018) underway in Barcelona, Spain. This conference, titled “New Perspectives for Improving 21st Century Health Systems”, has attracted over 3,700 professionals from all health care sectors. Attendees are learning about recent trends in health economics and outcomes research… Read more »

In Press: Real-world treatment outcomes of vedolizumab among Finnish IBD patients (FINVEDO)

A recently published real-world cohort study demonstrated that vedolizumab, an anti-integrin antibody, is an effective and well-tolerated treatment option for patients with inflammatory bowel disease (IBD).  The FINVEDO study showed high treatment persistence and improvements in disease activity, even in the case of refractory disease, for IBD patients treated with vedolizumab. To date, approximately 50,000… Read more »

MedEngine presented results from three new studies at the ISPOR congress in Glasgow

The 20th Annual European Congress of The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) was held in Glasgow, Scotland on Nov 4–8th 2017. The event attracted nearly 5000 participants from 77 countries and across all health care sectors. MedEngine participated in the congress, and presented results from three new real-world data research projects. ISPOR… Read more »

What is your real-world data strategy?

The entire pharmaceutical industry is built on various forms of data and has recently invested substantial resources towards collecting and analyzing real-world data (RWD). RWD has traditionally been viewed as a tool to primarily support market access and demonstrate product value. But when such data is used beyond the traditional applications, throughout the product lifecycle… Read more »

Knowledge-based management: Supporting health-related decision-making

The current trend towards a data-driven world is affecting everyone—including the pharmaceutical industry. As the volume and complexity of medical data grows and analytics methods continue developing, companies become more and more dependent on their ability to transform data into information that can be utilized in knowledge-based management, or KM. To get an insider’s view… Read more »

Beyond treating patients: Secondary uses of health and social data

Whether it be an encounter with a physician or nurse, a prescription for medication from a pharmacy, or admittance of a student loan—every contact that we have with health care personnel or the social security system generates data related to our health and well-being. Currently, the Finnish Ministry of Social Affairs and Health is preparing… Read more »






Eteläranta 14
00130 Helsinki

© 2019 MedEngine Oy